# A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

> **NCT04571424** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 33 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BIIB133 (Dapirolizumab pegol)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04571424
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571424, "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04571424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*